On August 23rd local time, Moderna, a US biopharmaceutical company, announced that the European Commission (EC) has approved the mRNA respiratory syncytial virus (RSV) vaccine mRESVIA& reg; (mRNA-1345) has been launched, and this vaccine is used to protect adults aged 60 and above from respiratory diseases caused by RSV infection.